Pulmonary fibrosis is an end-stage alteration in the respiratory disease characterized by fibroblast proliferation and massive accumulation of extracellular matrix and collagen associated with inflammatory damage. This disease is based on lung dysfunction and respiratory failure pathologically, and its incidence is rising year by year with the limited treatment method currently. Considering on regulation function in gut-lung axis, this dysbiosis caused by intestinal microflora not only modulates the immune response of the gastrointestinal tract but also can impact the onset process of chronic respiratory diseases including pulmonary fibrosis in a variety of ways. In addition, changes in microbial composition and function in the respiratory tract and the gut tract have recently been both linked to disorders in immune responses. In this opinion article, we summarize recent advances in the correlations and underlying pathogenic mechanisms of the relationship between intestinal microbiota and pulmonary fibrosis diseases, including multiple interventions of probiotics flora, diet and antibiotics against dysbiosis. However, direct evidence that pulmonary fibrosis injury changes the proportion of gut flora and composition of the metabolites in host is still lacking. Thus, this review can potentially provide effective theoretical and strategic support for the future exploration about regulatory mechanism and therapeutic drug development.